107726-13-6Relevant articles and documents
PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Paragraph 0168; 0175, (2015/02/18)
Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.
PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS
-
Page/Page column 107, (2010/10/03)
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular ltk activity.
Riluzole series. synthesis and in vivo 'antiglutamate' activity of 6- substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines
Jimonet, Patrick,Audiau, Fran?ois,Barreau, Michel,Blanchard, Jean-Charles,Boireau, Alain,Bour, Yvette,Coléno, Marie-Annick,Doble, Adam,Doerflinger, Gilles,Do Huu, Claudine,Donat, Marie-Hélène,Duchesne, Jean Marie,Ganil, Pierre,Guérémy, Claude,Honoré, Eliane,Just, Bernard,Kerphirique, Roselyne,Gontier, Sylvie,Hubert, Philippe,Laduron, Pierre M.,Blevec, Joseph Le,Meunier, Mireille,Miquet, Jean-Marie,Nemecek, Conception,Pasquet, Martine,Piot, Odile,Pratt, Jeremy,Rataud, Jean,Reibaud, Michel,Stutzmann, Jean-Marie,Mignani, Serge
, p. 2828 - 2843 (2007/10/03)
Two series of analogues of riluzole, a blocker of excitatory amino acid mediated neurotransmission, have been synthesized: monosubstituted 2- benzothiazolamines and 3-substituted derivatives. Of all the compounds prepared in the first series, only 2-benzothiazolamines bearing alkyl, polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent anticonvulsant activity against administration of glutamic acid in rats. The most active compounds displaying in vivo 'antiglutamate' activity were the 6-OCF3 (riluzole), 6-OCF2CF3, 6-CF3, and 6-CF2CF3 substituted derivatives with ED50 values between 2.5 and 3.2 mg/kg i.p. Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a β-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones. The most potent derivatives were 2-imino-3-(2-methylthio)- and 2-imino-3-(2- methylsulfinyl)-ethyl-6-trifluoromethoxybenzothiazolines (61 and 64, ED50 = 1.0 and 1.1 mg/kg i.p., respectively). In addition, intraperitoneal administration of some of the best benzothiazolines protected mice from mortality produced by hypobaric hypoxia.
